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OBJECTIVES: To assess the cost-effectiveness and budget
impact of using hexaminolevulinate (Hexvix) cystoscopy com-
pared to white light cystoscopy in any given population of
bladder cancer patients undergoing transurethral resection of
the bladder tumour (TURB). METHODS: The model is based
on the European Association of Urology (EAU) Guidelines on
bladder cancer, adjusted to current clinical practice in Italy. The
model compares the costs and outcomes for a cohort of 1000
patients with bladder cancer for 2 years from initial diagnosis
and treatment based on existing clinical practice: using stan-
dard white light cystoscopy for TURB guidance; or using
Hexvix cystoscopy for TURB guidance as an adjunct to stan-
dard white light cystoscopy. This allows calculation of the
incremental cost-effectiveness of Hexvix, based on Hexvix
changing patient management and reducing the recurrence rate.
RESULTS: To use Hexvix cystoscopy to guide TURB for all
patients, in the ﬁrst TURB and all the follow-up TURBs in
Italian population, is likely to result in additional costs of Euro
123,556—this represents an increase of 2.4% over total costs
with white light cystoscopy. However, this additional cost could
potentially deliver 95 fewer recurrences and 22,990 disease free
days for the treated population. The incremental cost of one
disease free year using Hexvix in all TURBs for all patients is
likely to be Euro 1,962. CONCLUSION: Bladder cancer is one
of the most expensive cancers to treat because of the combi-
nation of long survival and intensive, and costly, routine moni-
toring and treatment due to the recurrent nature of the disease.
Based on the treatment paths and assumptions deﬁned in the
inputs above, the model shows the likely impact of Hexvix
cystoscopy on the Italy bladder cancer population and overall
patient management costs and outcomes for 2 years from initial
diagnosis.
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OBJECTIVES: To estimate from a health service perspective the
impact of rational use (RU) of high costing chemotherapy
agents (HCCA). METHODS: A discussion forum with special-
ists was performed to optimize use of chemotherapy without
compromising patient prognosis within a tertiary cancer hospi-
tal. A consensus was reached within the clinical oncology staff
that restricted use of 2 drug candidates from the top 15 HCCA
would not be harmful to patient outcomes based on literature
data. These 15 drugs were responsible for 75% of overall che-
motherapy purchase cost. Gemcitabine was used predominantly
for 2nd line treatment of advanced breast cancer (BC) and 1st
line treatment of pancreas and bladder cancer. Epirubicin was
mainly used in adjuvant and palliative treatment of BC. Pre-
scription of chemotherapy was based on medical claims data
from outpatient drug administration between January 2005 and
December 2005. Medication costs were based on average
wholesale price for each drug. Substitution of epirubicin by
doxorubicin for the treatment of the majority of BC patients,
and the substitution of gemcitabine by other agents with equiva-
lent response rates for 2nd line treatment of advanced BC was
implemented in Janaury 2006. RESULTS: Together these two
drugs represented 15% of chemotherapy direct cost in 2005.
RU of these HCCA was responsible for 56% decline in median
prescription of gemcitabine per month (177.000 mg before
RU versus 78.000 mg after RU; p = 0.035). Similarly, median
prescription of epirubicin was reduced 81% per month
(148,000 mg before RU versus 28,000 mg after RU; p = 0.013)
from 2005 to 2006. This represented a cost saving strategy of
4% in the overall budget of chemotherapy purchase (annual
budget US$ 6.45 M in 2006). CONCLUSION: The RU of
HCCA drugs reduced the direct cost of chemotherapy unit and
allow us a better resource distribution.
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OBJECTIVES: Treatment of thyroid cancer consists of thy-
roidectomy and radio-iodine ablation (RAI) following TSH
stimulation. Thyroid hormone withdrawal (THW) and rhTSH
(Thyrogen, Genzyme) showed similar efﬁcacy in TSH stimula-
tion, but patients who receive rhTSH improved quality of life
by avoiding hypothyroidism symptoms. rhTSH reduces iodine
whole-body retention that would decrease the length of hospi-
talisation (LOS). However, rhTSH is an innovative drug which
has a cost to the pharmaceutical budget. This study aimed to
assess if there were savings due to shorter hospital LOS result-
ing from faster RAI clearance with rhTSH stimulation.
METHODS: Prospective case-control study, in which patients
stimulated by rhTSH were matched with patients stimulated by
THW. Individual time of discharge was calculated using indi-
vidual values of effective life-time, as the time to attain a
residual activity less than the threshold of 400 MBq. For each
method of stimulation, LOS was deﬁned as the time in order to
that 90% of patients would attain the threshold. The cost-
analysis was conducted from the hospital perspective. The cost
per hospital stay per RAI ablation was calculated as the sum of
variable costs (charges of drugs, laboratory and radiology tests
to perform one RAI) and ﬁxed costs (daily ﬁxed costs multi-
plicated by the LOS). RESULTS: The study included 52
patients (26 by group). For a threshold of 400 MBq, LOS of
patients stimulated by rhTSH was signiﬁcantly shorter than
LOS of patients stimulated by THW, with respectively 41 and
67 hours, p < 0.001. Fixed costs were 430€/day and variable
costs were respectively 315€ and 1115€/stay for stimulation by
THW and rhTSH. The cost per stay were respectively 1846€
and 2104€ for patients stimulated by THW and rhTSH. CON-
CLUSION: By increasing the iodine elimination, rhTSH allows
a decrease of the length of hospitalization, which partly com-
pensating for the cost of rhTSH acquisition.
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